Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware.
| Revenue (TTM) | $16.72M |
| Gross Profit (TTM) | $16.72M |
| EBITDA | $-81.17M |
| Operating Margin | -309.50% |
| Return on Equity | -95.30% |
| Return on Assets | -39.70% |
| Revenue/Share (TTM) | $0.21 |
| Book Value | $0.73 |
| Price-to-Book | 6.49 |
| Price-to-Sales (TTM) | 23.67 |
| EV/Revenue | 19.55 |
| EV/EBITDA | -0.54 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 41.00% |
| Shares Outstanding | $64.92M |
| Float | $27.59M |
| % Insiders | 13.80% |
| % Institutions | 64.49% |
Volatility is currently expanding
Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)
The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Prelude Therapeutics (PRLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the pricing of its underwritten offering of 18,018,014 shares of its voting common stock (the “Common Stock”) at a price of $4.44 per share, and, in lieu of Common Stock to investors who so chose, pre-funded warrants to purchase up to 2,252,252 shares of its Common Stock at a price of $4.4399 per pre-funded warrant, which represents the per share offering price for the Common Stock less the $0.0001 per share exercise price for each such pre-funded warrant. Before deducting the underwriting discounts and commissions and estimated offering expenses, the total gross proceeds to Prelude are approximately $90.0 million. The offering is expected to close on or about April 21, 2026, subject to the satisfaction of customary closing conditions.
Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer
